Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Revenue (2016 - 2025)

Historic Revenue for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $13.2 million.

  • Ocular Therapeutix's Revenue fell 2243.3% to $13.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $52.0 million, marking a year-over-year decrease of 1847.24%. This contributed to the annual value of $52.0 million for FY2025, which is 1847.37% down from last year.
  • Ocular Therapeutix's Revenue amounted to $13.2 million in Q4 2025, which was down 2243.3% from $14.5 million recorded in Q3 2025.
  • Ocular Therapeutix's Revenue's 5-year high stood at $17.1 million during Q4 2024, with a 5-year trough of $7.3 million in Q1 2021.
  • Moreover, its 5-year median value for Revenue was $13.4 million (2023), whereas its average is $13.5 million.
  • In the last 5 years, Ocular Therapeutix's Revenue surged by 64684.51% in 2021 and then plummeted by 2758.9% in 2025.
  • Over the past 5 years, Ocular Therapeutix's Revenue (Quarter) stood at $12.3 million in 2021, then increased by 14.36% to $14.1 million in 2022, then increased by 5.16% to $14.8 million in 2023, then rose by 15.41% to $17.1 million in 2024, then dropped by 22.43% to $13.2 million in 2025.
  • Its last three reported values are $13.2 million in Q4 2025, $14.5 million for Q3 2025, and $13.5 million during Q2 2025.